Search Omvoh (mirikizumab-mrkz) injection (type in keywords)
Search Medical Information
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ® (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How is Omvoh® (mirikizumab-mrkz) metabolized and eliminated?
Mirikizumab is expected to be degraded into small peptides and amino acids via catabolic pathways. In pharmacokinetic analyses, the mean half-life was 9.3 days.
Degradation and Clearance
Mirikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.1
In patients with ulcerative colitis, the
- geometric mean (CV%) clearance was 0.0229 L/h (34%), and
- geometric mean (CV%) elimination half-life was 9.3 days (40%).1
Enclosed Prescribing Information
Reference
1Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: February 18, 2025
Are you satisfied with this content?